Latest news with #TomAdams
BBC News
10-04-2025
- BBC News
Drone used to smuggle drugs and phones found outside Whitemoor
A man has been jailed after a drone used to smuggle drugs and phones crashed outside a Woodall's DNA was on cargo from the crashed drone, which was found in 2023 by a dog handler patrolling HMP Whitemoor in March, said Woodall was arrested the following year when he was seen acting suspiciously outside another prison in 32-year-old, of Yorke Avenue, Brierley Hill, West Midlands, admitted two counts of conspiring to convey prohibited items into a prison, and he was jailed for two years and six months. Police said the package of goods worth more than £200,000 was found on 13 November 2023.A vehicle linked to Woodall seen in the area was scrapped following the said the attempt followed an incident in August 2023 when a driver was stopped by police on the A1, near Catterick, North had the address for HMP Durham in a sat nav, a drone in the back of the vehicle and a package containing cannabis, tobacco and fingerprints were found on the drone and a phone number linked to him in the man's contacts list, police said. At 04:00 GMT on 12 February last year, police received a call from HMP The Mount, near Hemel Hempstead, Hertfordshire, when CCTV operators saw Woodall acting suspiciously in nearby officers arrived, he tried to dispose of his phone and was was sentenced at Peterborough Crown Court on Con Tom Adams said: "We're working hard with prison staff to tackle the issue of smuggling, and we take the matter extremely seriously."This was a large package containing drugs and mobile phones that could have caused significant issues within the prison and been used in criminality."I'm pleased the attempt was unsuccessful and Woodall has now found himself behind bars." Follow Cambridgeshire news on BBC Sounds, Facebook, Instagram and X.
Yahoo
13-03-2025
- Business
- Yahoo
KORU Medical Systems Inc (KRMD) Q4 2024 Earnings Call Highlights: Record Revenues and Strategic ...
Release Date: March 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. KORU Medical Systems Inc (NASDAQ:KRMD) achieved record-setting revenues in the fourth quarter, with a 23% increase, and full-year revenues grew by 18%. The company expanded its gross margins, achieving a record-setting gross profit for the full year 2024. KORU Medical Systems Inc (NASDAQ:KRMD) successfully entered multiple new international geographies, contributing to a 32% growth in international revenues. The company added four new collaborations to its novel therapies pipeline in 2024, with two more announced in early 2025. KORU Medical Systems Inc (NASDAQ:KRMD) maintained a strong cash position, ending the year with a cash balance of $9.6 million, exceeding expectations. The novel therapies segment is subject to revenue lumpiness, which could impact overall financial performance. The company faces potential challenges from tariffs, although the impact is expected to be minimal. There is a dependency on the immunoglobulin market, which currently accounts for 90% of total revenues. The FDA's announcement regarding the voluntary withdrawal of certain immunoglobulin lots could pose a short-term risk. The company's guidance for 2025 indicates a deceleration in revenue growth compared to 2024. Warning! GuruFocus has detected 4 Warning Signs with KRMD. Q: Can you break down the 2025 growth assumptions for domestic and international markets, and the expected contribution from pharma services and clinical trials? A: Tom Adams, CFO: For domestic growth, we expect between 10% and 15% revenue growth. Internationally, we anticipate over 20% growth as we expand in that region. For novel therapies, we expect around $2 to $3 million in revenue from NRE and clinical product sales. Q: What factors are driving above-market growth domestically and internationally in 2025? A: Tom Adams, CFO: Internationally, we are seeing growth from entering new geographies and expanding in existing ones, such as Japan. Domestically, we continue to add new customers and see market growth due to increased diagnosis of infections. Q: Can you provide an update on the oncology opportunity and what remains to be done for filing? A: Linda Tharby, CEO: We are confident about FDA approval. Our focus is on market assessment, proving our value proposition, understanding reimbursement, and establishing a new distribution partner in the US. Progress is being made in all areas. Q: How did the core domestic business outperform market growth in the fourth quarter, and can this growth be replicated? A: Linda Tharby, CEO: The team used AI to identify growth opportunities, signed new agreements, and implemented a price increase. While 20% growth may not be consistent, we are confident in 10% to 15% growth, with potential upside from new account wins and market growth. Q: How does the international expansion impact working capital and cash flow positivity for the year? A: Tom Adams, CFO: The international expansion is factored into our guidance. We are aware of longer payment terms and have planned inventory levels accordingly. We expect to be operational cash flow positive and have sufficient capital for strategic opportunities. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
